MHLW Adds Label Warnings To Astellas Protopic Ointment
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare added warning information to Astellas' atopic dermatitis drug Protopic (tacrolimus) ointment Sept. 25. The ministry ordered the company to add in the warning label that even though no link has been found, cases of lymphoma and skin cancer were reported. The ministry cited that there is on average one such case reported in Japan every year. (Click here for more - Japanese language
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.